november, 2022

Warning: in_array() expects parameter 2 to be array, bool given in /home/customer/www/ on line 61

01nov5:30 pm6:30 pmMineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease

Event Details

Credits Available: CME, ABIM MOC

Mineralocorticoid Receptor Antagonists: Addressing Residual Risk in Patients with Cardiac Disease, T2DM, and CKD will provide cardiologists with information about the interrelationship of CVD and renal disease and the efficacy and safety of MRAs as well as expert guidance about the role of MRAs in the management of patients with T2DM, CKD, and CVD.

Learning Objectives:

At the conclusion of this activity, participants should be able to:

  • Discuss the role of the mineralocorticoid receptor in the development and progression of renal and cardiovascular disease.
  • Evaluate for and monitor CKD in patients with T2DM and cardiac disease.
  • Assess the data for the efficacy and safety of approved mineralocorticoid receptor antagonists.
  • Incorporate mineralocorticoid receptor antagonists into management plans for patients with CKD, T2DM, and cardiovascular disease.


Jointly provided by PCME and Rockpointe. This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.



(Tuesday) 5:30 pm - 6:30 pm(GMT-07:00) View in my time

Submit a Comment

Your email address will not be published.